Browse News
Filter News
Found 4,124 articles
-
While Pfizer has ended one of its two Phase III studies for inclacumab in sickle cell disease, the company is still eyeing an approval for the antibody in the inherited blood disorder by 2026.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Vertex and CRISPR Therapeutics are setting up treatment centers for patients with beta thalassemia and sickle cell disease to compete with bluebird’s established infrastructure.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Synthego Announces CEO Transition to Focus on Enabling CRISPR Therapeutics
3/27/2024
Synthego Corporation, a leading provider of genome engineering solutions, announced that Paul Dabrowski will step down as Chief Executive Officer, effective immediately.
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
3/27/2024
Precision BioSciences, Inc. announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
-
Integrated DNA Technologies Unveils New Custom Vector Onboarding Tool to Optimize Gene Synthesis
3/27/2024
Global genomics solutions provider Integrated DNA Technologies is expanding its gene synthesis offerings with a new custom vector onboarding tool.
-
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
3/27/2024
Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today reported financial results for the full year ended December 31, 2023, and additional business updates.
-
Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics
3/26/2024
Function Oncology, a company transforming the operating system of precision medicine with CRISPR-powered platform technology, announced an innovative research and development partnership with Volastra Therapeutics, a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability.
-
Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration
3/26/2024
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr.
-
Ubiquitous potential, possible safety advantages and the recent growth of cell and gene therapy are driving investment in a different type of genetic editing.
-
Nkarta Announces Pricing of $240 Million Underwritten Offering
3/25/2024
Nkarta, Inc. announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock.
-
Researchers at Phoenix Children's First in the World to Produce Mouse Lungs in Rats
3/25/2024
Research conducted at the Phoenix Children's Research Institute at the University of Arizona College of Medicine — Phoenix reports the successful generation of a mouse lung in a rat, according to a paper published in the American Journal of Respiratory and Critical Care Medicine.
-
Tegoprubart, Eledon Pharmaceuticals’ experimental anti-CD40L antibody, was part of the immunosuppressive treatment regimen used following the first-ever transplant of a kidney from a genetically modified pig to a human.
-
Fluent Biosciences announces early access availability of transformative direct-guide capture for single cell analysis for complex CRISPR screening in Particle-templated Instant Partitions (PIPseq-CRISPR)
3/21/2024
Fluent BioSciences, a life sciences company focused on making single-cell analysis simple and accessible to every researcher, announces early access availability of new kits and reagents for direct CRISPR guide capture in particle templated instant partitions (PIPseq-CRISPR).
-
Intranasal Delivery of shRNA Edits to Silence 5-HT2A Receptor Shows Promise in Enhancing Memory and Alleviating Anxiety
3/21/2024
Scientists from Cognigenics have made significant progress in developing precision-based therapeutics for neurological disorders.
-
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
3/21/2024
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2023.
-
Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits powered by Ultima Genomics sequencing, prototype kits now shipping
3/21/2024
Fluent BioSciences is thrilled to announce the award of an NIH Small Business Innovation Research (SBIR) Phase II grant, funded by the National Institute of General Medical Sciences (NIGMS, 2 R44 GM137648).
-
Two days after winning FDA approval, Orchard Therapeutics on Wednesday provided its U.S. launch plans for metachromatic leukodystrophy gene therapy Lenmeldy, which has a wholesale acquisition cost of $4.25 million for the one-time treatment.
-
Semarion Introduces SemaCyte Multiplexing Platform to Enhance Cell Assay Data Quality and Speed During Drug Discovery
3/20/2024
Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, introduced its SemaCyte® Multiplexing Platform, an expansion to the existing SemaCyte Microcarrier platform to utilize optical barcoding to accelerate screening processes during in vitro drug discovery.